Skip to main content

Advertisement

Table 2 Clinical assessments and outcomes at inclusion and during follow-up

From: Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis

Measure Inclusion (n = 165) 18 months (n = 156) 30 months (n = 149)
Mean M-HAQ score (median) 0.93 ± 0.64 (0.875) 0.42 ± 0.50 (0.25) 0.35 ± 0.41 (0.25)
No. with M-HAQ ≥ 1.0 (%) 76 (46.1) 18 (11.6%) 17 (11.5%)
Mean DAS28-3 score (median) 5.01 ± 1.27 (4.94) 2.94 ± 1.26 (2.66) 2.81 ± 1.06 (2.46)
No. with DAS28-3 < 2.6 (%) 5 (3.0) 76 (48.7) 82 (55.0)
Mean swollen joint count (median) 12.55 ± 9.57 (10) 2.83 ± 5.51 (0) 2.04 ± 3.64 (0)
Number without synovitis (%) n.a. 72 (46.2) 82 (55.0)
Number with persistent arthritis (%) n.a. 137 (87.8) 125 (83.9)
No. fulfilling criteria for RA (%) 133 (80.6) 36 (23.1) 28 (18.8)
No. with severe arthritis (%) 106 (64.2) 65 (41.7) 56 (37.8)
Mean total SvH score (median) 6.05 ± 8.38 (4) 11.34 ± 13.82 (7) 15.76 ± 18.38 (10)
Mean erosion SvH score (median) 3.02 ± 4.99 (1) 6.94 ± 9.37 (4) 10.31 ± 13.14 (7)
Upper third of the total SvH score >5 >10 >15
No. on DMARDs (%)    
   Total 31 (18.8) 120 (76.9) 116 (77.9)
   RF-positive 13/68 (19.1) 60/63 (95.2) 60/61 (98.4)
   Anti-CCP-positive 10/53 (18.9) 49/52 (94.2) 50/51 (98.0)
   Anti-Sa-positive 6/46 (13.0) 43/45 (95.6) 44/44 (100.0)
  1. CCP, cyclic citrullinated peptide; DAS28-3, Disease Activity Score using 28 joints and 3 variables (tender and swollen joint counts and C-reactive protein); M-HAQ, modified Health Assessment Questionnaire; n.a., not applicable; RF, rheumatoid factor; SvH, Sharp–van der Heijde. Where errors are shown, results are means ± SD.